Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Shares (ADSs) resulting from employee benefit plan transactions.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of equity ownership changes and does not contain financial performance data.
Material Changes
The filing details specific changes in shareholdings held by employee trusts and plans in which directors have a potential interest:
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the fund decreased from 18,426,913 to 18,330,144 on February 10, 2005, at an average price of $44.65.
- GSK Trust (Ordinary Shares): On February 11, 2005, the Trust transferred 6,282 shares to the SmithKline Beecham Mid Term Incentive Plan, 719,117 shares to the GlaxoSmithKline Performance Share Plan, and 26,426 shares to the SmithKline Beecham Employee Share Option Plan 1991.
- GSK US Trust (ADSs): On February 11, 2005, the Trust transferred 1,215 American Depositary Shares to participants in the GlaxoSmithKline Performance Share Plan.
- Scientific Advisory Board: 318 ADSs were purchased for Dr. L. Shapiro on February 11, 2005, at a price of $46.41.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting compliance with securities regulations regarding director share interests.
Key Facts for Investor Verification
- Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe have potential interests in shares held by the GSK Trust and GSK US Trust.
- Directors Dr. J-P Garnier and Dr. T Yamada have potential interests in the GlaxoSmithKline US Retirement Savings Plan.
- Specific share transfers occurred on February 11, 2005, affecting the SmithKline Beecham Mid Term Incentive Plan, GlaxoSmithKline Performance Share Plan, and SmithKline Beecham Employee Share Option Plan 1991.
- The filing confirms the company's status as a foreign issuer filing under Form 20-F.